1. Introduction {#sec1-jcm-09-00493}
===============

Lidocaine is an attractive regional anesthetic for ambulatory surgery. It offers a rapid onset and fast recovery of both motor and sensory block \[[@B1-jcm-09-00493]\]. However, when compared with other local anesthetics, the use of lidocaine in spinal anesthesia has been known to be associated with increased risk of transient neurological symptoms (TNS) \[[@B2-jcm-09-00493],[@B3-jcm-09-00493]\], hindering its application in ambulatory spinal anesthesia. Other local anesthetics including mepivacaine, low-dose bupivacaine, procaine, articaine, levobupivacaine, ropivacaine and 2-chloroprocaine have been suggested as replacement drugs.

TNS generally occurs in patients with single injection spinal anesthesia within the first 24 hours \[[@B2-jcm-09-00493]\]. TNS consists of pain in the lower extremities without abnormalities in neurologic and radiologic examination \[[@B2-jcm-09-00493]\]. In previous systematic reviews and meta-analyses \[[@B2-jcm-09-00493],[@B3-jcm-09-00493]\], lidocaine has a significantly higher relative risk of developing TNS compared with most other local anesthetics, but the previous meta-analyses lacked data on ropivacaine, levobupivacaine, and chloropocaine; thus, more evaluations are still needed to confirm favorable results for these aforementioned local anesthetics. In the last decade, many randomized controlled trials (RCTs) comparing between the incidence of TNS after lidocaine and other local anesthetics have been conducted. More subsequent studies evaluating the effect of lidocaine on the risk of TNS have been published \[[@B2-jcm-09-00493],[@B3-jcm-09-00493]\]. Furthermore, among them, many studies reported no patients suffering from TNS after spinal anesthesia with lidocaine \[[@B4-jcm-09-00493],[@B5-jcm-09-00493],[@B6-jcm-09-00493],[@B7-jcm-09-00493],[@B8-jcm-09-00493],[@B9-jcm-09-00493],[@B10-jcm-09-00493],[@B11-jcm-09-00493],[@B12-jcm-09-00493],[@B13-jcm-09-00493],[@B14-jcm-09-00493],[@B15-jcm-09-00493],[@B16-jcm-09-00493],[@B17-jcm-09-00493],[@B18-jcm-09-00493]\]. Therefore, it is still controversial on the safety of lidocaine for spinal anesthesia during ambulatory surgery in terms of TNS. The objective of this systematic review and meta-analysis is to compare the incidence of TNS between lidocaine and other local anesthetics and to evaluate the frequency of TNS with various types of local anesthetics in adult surgical patients after spinal anesthesia.

2. Materials and Methods {#sec2-jcm-09-00493}
========================

2.1. Literature Search {#sec2dot1-jcm-09-00493}
----------------------

This systematic review and meta-analysis was conducted according to the Preferred Items for Systematic Reviews and Meta Analyses (PRISMA) statements guideline \[[@B19-jcm-09-00493]\]. A predefined protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42019137819). RCTs comparing lidocaine versus other local anesthetics during spinal anesthesia were searched on the following databases: PubMed, EMBASE, CENTRAL, CINAHL, Scopus, Web of Science and KoreaMed. The final search was performed on March 31st, 2019. Search strategies were established with MeSH terms and keywords, including "spinal anesthesia", "lidocaine", or "lignocaine". Each finding was combined with the Boolean operator, such as "AND", "OR". Detailed search strategies for each database were described in [Table S1](#app1-jcm-09-00493){ref-type="app"}. The title, abstract, and authors of all retrieved articles were extracted and collected, regardless of the publication year, language or region.

2.2. Study Selection {#sec2dot2-jcm-09-00493}
--------------------

C.-H.K. and H.-J.S. independently accessed the titles and abstracts of the articles to screen for relevant studies. Subsequently, full-texts of relevant articles were obtained via hand-search, library service or contacting the authors. C.-H.K. and J.-H.R. read the full text to select studies that were appropriate for this meta-analysis. The inclusion criteria were (1) randomized controlled trials, (2) surgical patients under spinal anesthesia, (3) lidocaine use for spinal anesthesia in at least in one group, and (4) use of other local anesthetic for spinal anesthesia in the control group. The exclusion criteria were: (1) abstract, protocol, conference poster or review; and (2) The study which did not report the incidence of TNS. S.-H.H. participated on selection if any disagreement existed.

2.3. Data Extraction {#sec2dot3-jcm-09-00493}
--------------------

C.-H.K. and H.-J.S. independently investigated and collected the following data from final full-texts: author, publication year, language, sample size, type of surgery, type of anesthesia, patient's position during surgery, needle type, characteristics of lidocaine (concentration, baricity, dose, and adjuvants), characteristics of local anesthetics used in the control group (type, concentration, baricity, dose, and adjuvants) and the incidence of TNS.

2.4. Risk of Bias Assessment {#sec2dot4-jcm-09-00493}
----------------------------

C.-H.K. and J.-H.R. independently assessed the risk of bias of the included studies using the Cochran Risk of Bias tool \[[@B20-jcm-09-00493]\]. It consists of seven items: random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessors, incomplete outcome data, selective reporting, and other biases. Each item was graded as low, unclear or high. S.-H.H. settled any disagreements between the aforementioned assessors.

2.5. Data Synthesis and Statistical Analysis {#sec2dot5-jcm-09-00493}
--------------------------------------------

Data synthesis and meta-analysis were performed using Revman 5.3 software (Cochrane Collaboration, Oxford, UK) and R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria). Since the incidence of TNS was dichotomous variable, the authors calculated the risk ratio (RR) as a pooled estimate. The inverse variance method and random effect models were employed. A continuity correction of 0.5 was applied to zero total events trials \[[@B21-jcm-09-00493]\]. The findings were presented as a forest plot with 95% confidence intervals. A subgroup analysis was conducted according to the local anesthetics which were used in the control group. Additional subgroup analyses were carried out to investigate any relationship between the incidence of TNS and baricity/concentration. The heterogeneity among the studies was evaluated by I^2^ statistic. I^2^ could be interpreted in the following manner: 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% considerable heterogeneity \[[@B22-jcm-09-00493]\]. A publication bias was assessed by construction of a funnel plot and the linear regression test. Sensitivity analysis (leave one study out) was conducted to confirm the robustness of the results.

3. Results {#sec3-jcm-09-00493}
==========

3.1. Descriptions of Trials {#sec3dot1-jcm-09-00493}
---------------------------

A total of 4515 articles were found on the initial database search. Among them, 2493 articles were removed due to duplication. Subsequently, 2202 articles and 168 articles were considered as irrelevant based on their title and abstract, respectively. The full-text of 123 articles were evaluated, and then, 84 articles were excluded due to the following reasons: no results about the incidence of TNS (*n* = 42); no other local anesthetics were used (*n* = 18); conference posters (*n* = 7); abstracts only (*n* = 4); protocols (*n* = 4); healthy subjects (*n* = 4); non-randomized studies of intervention (*n* = 2); different anesthetic techniques between groups (*n* = 1); mixed spinal anesthetics (*n* = 1); and a brief report (*n* = 1). Therefore, a total of 39 RCTs were included in the final analysis ([Figure 1](#jcm-09-00493-f001){ref-type="fig"}) \[[@B4-jcm-09-00493],[@B5-jcm-09-00493],[@B6-jcm-09-00493],[@B7-jcm-09-00493],[@B8-jcm-09-00493],[@B9-jcm-09-00493],[@B10-jcm-09-00493],[@B11-jcm-09-00493],[@B12-jcm-09-00493],[@B13-jcm-09-00493],[@B14-jcm-09-00493],[@B15-jcm-09-00493],[@B16-jcm-09-00493],[@B17-jcm-09-00493],[@B18-jcm-09-00493],[@B23-jcm-09-00493],[@B24-jcm-09-00493],[@B25-jcm-09-00493],[@B26-jcm-09-00493],[@B27-jcm-09-00493],[@B28-jcm-09-00493],[@B29-jcm-09-00493],[@B30-jcm-09-00493],[@B31-jcm-09-00493],[@B32-jcm-09-00493],[@B33-jcm-09-00493],[@B34-jcm-09-00493],[@B35-jcm-09-00493],[@B36-jcm-09-00493],[@B37-jcm-09-00493],[@B38-jcm-09-00493],[@B39-jcm-09-00493],[@B40-jcm-09-00493],[@B41-jcm-09-00493],[@B42-jcm-09-00493],[@B43-jcm-09-00493],[@B44-jcm-09-00493],[@B45-jcm-09-00493],[@B46-jcm-09-00493]\].

All these RCTs compared lidocaine with other local anesthetics (bupivacaine, prilocaine, mepivacaine, levobupivacaine, chloroprocaine, ropivacaine, procaine, articaine, or sameridine) and reported the incidence of TNS. We found that 28 RCTs had two groups \[[@B4-jcm-09-00493],[@B5-jcm-09-00493],[@B6-jcm-09-00493],[@B7-jcm-09-00493],[@B8-jcm-09-00493],[@B9-jcm-09-00493],[@B10-jcm-09-00493],[@B11-jcm-09-00493],[@B12-jcm-09-00493],[@B14-jcm-09-00493],[@B15-jcm-09-00493],[@B18-jcm-09-00493],[@B23-jcm-09-00493],[@B26-jcm-09-00493],[@B27-jcm-09-00493],[@B29-jcm-09-00493],[@B30-jcm-09-00493],[@B34-jcm-09-00493],[@B35-jcm-09-00493],[@B36-jcm-09-00493],[@B37-jcm-09-00493],[@B38-jcm-09-00493],[@B39-jcm-09-00493],[@B40-jcm-09-00493],[@B41-jcm-09-00493],[@B42-jcm-09-00493],[@B44-jcm-09-00493],[@B46-jcm-09-00493]\] of lidocaine more than other local anesthetics, while 11 RCTs had multiple groups \[[@B13-jcm-09-00493],[@B16-jcm-09-00493],[@B17-jcm-09-00493],[@B24-jcm-09-00493],[@B25-jcm-09-00493],[@B28-jcm-09-00493],[@B31-jcm-09-00493],[@B32-jcm-09-00493],[@B33-jcm-09-00493],[@B43-jcm-09-00493],[@B45-jcm-09-00493]\]. Five out of 11 RCTs have more than two lidocaine groups \[[@B16-jcm-09-00493],[@B24-jcm-09-00493],[@B28-jcm-09-00493],[@B33-jcm-09-00493],[@B43-jcm-09-00493]\]. According to the Cochrane guidelines \[[@B22-jcm-09-00493]\], all lidocaine groups were pooled into a single group. In another five RCTs, more than two other local anesthetics were used for spinal anesthesia \[[@B17-jcm-09-00493],[@B25-jcm-09-00493],[@B31-jcm-09-00493],[@B32-jcm-09-00493],[@B45-jcm-09-00493]\]. In the remaining RCT \[[@B13-jcm-09-00493]\], three doses of sameridine were used for spinal anesthesia and the results of three sameridine groups were combined. Patients who received general anesthesia due to insufficient spinal block were excluded from the final analysis because it was unclear whether local anesthetics were administered in the cerebrospinal fluid. Details of each trial are summarized in [Table 1](#jcm-09-00493-t001){ref-type="table"}. The 5% hyperbaric lidocaine was most used, followed by 2% isobaric. The dose of lidocaine used in each trial varied from 10 to 100mg. Specific details, including concentration, baricity, doses and adjuvants of study drugs, are summarized in [Table 2](#jcm-09-00493-t002){ref-type="table"}.

3.2. Methodology Quality and Risk of Bias {#sec3dot2-jcm-09-00493}
-----------------------------------------

The methodology quality and risk of bias are summarized in [Figure 2](#jcm-09-00493-f002){ref-type="fig"}. In each study, all patients were randomized to receive intrathecal lidocaine or other local anesthetics; however, the randomization method was unclear in eight studies. Twenty one studies maintained allocation concealment, but the other studies failed to describe it clearly. The risk of performance bias was high in 9 studies and unclear in 20 studies. It might be important for anesthesiologists to be aware of drugs for patient safety and sufficient block when performing spinal anesthesia. Unlike performance bias, the risk of detection bias was low overall. The risk of attrition bias, reporting bias, and other biases were low in more than 75% of the studies evaluated. Reasons for each risk of bias are shown in [Table S2](#app1-jcm-09-00493){ref-type="app"}.

3.3. Outcome Synthesis {#sec3dot3-jcm-09-00493}
----------------------

A total of 39 studies included 4733 patients; 2209 patients were allocated to the lidocaine group and 2524 patients to the control group. The incidence of TNS was 10.8% (238/2209) in the lidocaine group and was 2.2% (56/2524) in the control group. The risk of TNS after spinal anesthesia was significantly higher in the lidocaine group than in the control group (Risk ratio (RR) = 4.12, 95% confidence interval (CI) = 3.13 to 5.43, *p* \< 0.001), with a low level of heterogeneity (I^2^ = 0%, *p* = 0.61) ([Figure 3](#jcm-09-00493-f003){ref-type="fig"}). A symmetrical funnel plot and linear regression test showed insignificant results for publication bias (*p* = 0.206) ([Figure S1](#app1-jcm-09-00493){ref-type="app"}). Sensitivity analysis revealed the robustness of the results ([Table S3](#app1-jcm-09-00493){ref-type="app"}). Omitting one study \[[@B28-jcm-09-00493]\] decreased the RR to 3.51, but still maintained the significance.

In subgroup analysis as shown in [Figure 4](#jcm-09-00493-f004){ref-type="fig"}, lidocaine increased the incidence of TNS compared with most other local anesthetics, such as bupivacaine (RR = 4.79, 95% CI = 3.31 to 6.94, *p* \< 0.001), levobupivacaine (RR = 5.1, 95% CI = 2.37 to 11.0, *p* \< 0.001), prilocaine (RR = 4.94, 95% CI = 1.89 to 12.9, *p* = 0.001), chloroprocaine (RR = 5.24, 95% CI = 1.11 to 24.76, *p* = 0.037), procaine (RR = 6.74, 95% CI = 1.88 to 24.13, *p* = 0.003), and articaine (RR = 4.5, 95% CI = 1.94 to 10.42, *p* \< 0.001). However, no significant difference was observed between the lidocaine group and the mepivacaine (RR = 0.82, 95% CI = 0.27 to 2.48, *p* = 0.728), ropivacaine (RR = 5.92, 95% CI = 0.99 to 35.47, *p* = 0.052) or sameridine group (RR = 3.34, 95% CI = 0.07 to 164.98, *p* = 0.545). A low level of heterogeneity was found in each subgroup analysis.

The relationship between the incidence of TNS and baricity or concentration is shown in [Figure 5](#jcm-09-00493-f005){ref-type="fig"}. Sixteen studies used hyperbaric lidocaine \[[@B5-jcm-09-00493],[@B6-jcm-09-00493],[@B11-jcm-09-00493],[@B13-jcm-09-00493],[@B15-jcm-09-00493],[@B16-jcm-09-00493],[@B18-jcm-09-00493],[@B28-jcm-09-00493],[@B32-jcm-09-00493],[@B33-jcm-09-00493],[@B34-jcm-09-00493],[@B35-jcm-09-00493],[@B36-jcm-09-00493],[@B39-jcm-09-00493],[@B42-jcm-09-00493],[@B45-jcm-09-00493]\], 12 studies used isobaric \[[@B14-jcm-09-00493],[@B17-jcm-09-00493],[@B23-jcm-09-00493],[@B24-jcm-09-00493],[@B25-jcm-09-00493],[@B26-jcm-09-00493],[@B27-jcm-09-00493],[@B29-jcm-09-00493],[@B30-jcm-09-00493],[@B31-jcm-09-00493],[@B41-jcm-09-00493],[@B44-jcm-09-00493]\], and 4 studies used hypobaric lidocaine for spinal anesthesia \[[@B4-jcm-09-00493],[@B7-jcm-09-00493],[@B26-jcm-09-00493],[@B33-jcm-09-00493]\]. One study had two treatment groups that administered hyperbaric or isobaric lidocaine \[[@B43-jcm-09-00493]\]. Since 6 studies failed to report the baricity of lidocaine \[[@B10-jcm-09-00493],[@B12-jcm-09-00493],[@B37-jcm-09-00493],[@B38-jcm-09-00493],[@B40-jcm-09-00493],[@B46-jcm-09-00493]\], those RCTs were excluded from subgroup analysis. The risk of TNS was higher in the lidocaine group compared with the control group when hyperbaric (RR = 3.59, 95% CI = 2.03 to 6.33, *p* \< 0.001) or isobaric lidocaine (RR = 4.45, 95% CI = 2.86 to 6.93, *p* \< 0.001) was used. However, there were no differences between the two groups with respect to the risk of TNS when hypobaric lidocaine was administered (RR = 1.00, 95% CI = 0.14 to 6.99, *p* = 1.00). As shown in [Table 2](#jcm-09-00493-t002){ref-type="table"}, the concentration used in each study varied from 0.3% to 5%. Two studies have multiple groups with different concentration \[[@B16-jcm-09-00493],[@B43-jcm-09-00493]\]. Most studies used 2% or 5% lidocaine and subgroups were categorized into 3 groups: (1) 5%, (2) 2%≤ \<5%, and (3) \<2%. The incidence of TNS was significantly higher in the lidocaine group compared with the control group in all categories (5%: RR = 5.23, 95% CI = 3.40 to 8.05, *p* \< 0.001; 2%≤ \<5%: RR = 3.53, 95% CI = 2.03 to 6.12, *p* \< 0.001; \<2%: RR = 3.28, 95% CI = 1.24 to 8.71, *p* = 0.017).

4. Discussion {#sec4-jcm-09-00493}
=============

The present meta-analysis confirmed that lidocaine used for spinal anesthesia still causes TNS more frequently than most other local anesthetics (bupivacaine, levobupivacaine, prilocaine, chloroprocaine, procaine, and articaine) except for mepivacaine, ropivacaine or sameridine. This is the first study that analyzed the role of baricity and concentration of lidocaine as potential risk factors for TNS, and the subgroup analysis showed that hyperbaric and isobaric lidocaine showed higher TNS rates than the others, and higher rates of TNS have been observed in all concentration categories of lidocaine.

The incidence of TNS of lidocaine was about 4 times higher than that of other local anesthetics in this study, which supported the result of the previous meta-analysis by Zaric et al. \[[@B2-jcm-09-00493]\] which included 16 RCTs with a total of 1467 patients. Since then, many RCTs have been still conducted to compare the incidence of TNS between lidocaine and other local anesthetics. A recent meta-analysis including 24 studies with 2226 patients compared the risk of TNS by using direct and indirect comparison \[[@B3-jcm-09-00493]\]. However, in this meta-analysis, more RCTs, including 39 studies with 4733 patients (more than twice) were analyzed and lidocaine was compared with more various local anesthetics. However, the risk ratio and prevalence of developing TNS of the current study was slightly lower than those of the previous studies; Zaric et al. (risk ratio 4.62, prevalence 14.2%) \[[@B2-jcm-09-00493]\], Forget et al. (prevalence 18%) \[[@B3-jcm-09-00493]\]. These difference can be explained in part by that many RCTs of the present meta-analysis reported no case of TNS in the lidocaine group \[[@B4-jcm-09-00493],[@B5-jcm-09-00493],[@B6-jcm-09-00493],[@B7-jcm-09-00493],[@B8-jcm-09-00493],[@B9-jcm-09-00493],[@B10-jcm-09-00493],[@B11-jcm-09-00493],[@B12-jcm-09-00493],[@B13-jcm-09-00493],[@B14-jcm-09-00493],[@B15-jcm-09-00493],[@B16-jcm-09-00493],[@B17-jcm-09-00493],[@B18-jcm-09-00493]\], and a continuity correction of 0.5 was applied to these zero total events trials to prevent the overestimation of the risk of TNS \[[@B21-jcm-09-00493]\]. Among other local anesthetics, chloroprocaine and mepivacaine have similar characteristics with lidocaine in terms of rapid onset time and short duration \[[@B47-jcm-09-00493],[@B48-jcm-09-00493]\]. Subgroup analysis suggested that the incidence of TNS of chloroprocaine was lower than that of lidocaine. This finding significantly differs from the previous results \[[@B2-jcm-09-00493],[@B3-jcm-09-00493]\]. However, the previous meta-analyses included only one or two RCTs comparing the effect of lidocaine and chloroprocaine. This study included four RCTs and no case of TNS in the chloroprocaine group was reported \[[@B17-jcm-09-00493],[@B24-jcm-09-00493],[@B26-jcm-09-00493],[@B46-jcm-09-00493]\]. This would appear to indicate that chloroprocaine may be an attractive alternative to lidocaine for the short ambulatory surgery with fast onset and quick recovery time \[[@B48-jcm-09-00493]\]. On the other hand, there was no difference in the incidence of TNS between lidocaine and mepivacaine, which was consistent with the result of the previous studies \[[@B2-jcm-09-00493],[@B3-jcm-09-00493]\]. The idea that ropivacaine could decrease the development of TNS is still controversial. Although Zaric et al. \[[@B2-jcm-09-00493]\] found that there was no difference in the risk of TNS between lidocaine and ropivacaine, Forget et al. \[[@B3-jcm-09-00493]\] found that ropivacaine could decrease the risk of TNS than lidocaine. However, as expected, two studies included smaller number of studies and the latter study estimated pooled effect size by mostly indirect comparison. Surprisingly, the present study found more studies comparing the effect of lidocaine and ropivacaine, and estimated the pooled effect size by using a direct comparison.

Subgroup analysis suggested that no cases of TNS were found in the hypobaric lidocaine group whereas previous studies showed that the TNS of the lidocaine group occurred regardless of the baricity and concentration \[[@B49-jcm-09-00493],[@B50-jcm-09-00493],[@B51-jcm-09-00493]\]. This result can be explained by low doses (10--20 mg) of hypobaric lidocaine group administered. Ben-David et al. \[[@B52-jcm-09-00493]\] also reported that small doses of hypobaric lidocaine reduced the risk of TNS more than large doses of hypobaric lidocaine. However, this needs to be interpreted with caution since low doses of local anesthetics may be insufficient for adequate regional block \[[@B53-jcm-09-00493]\]. Regarding the concentration of lidocaine, higher rates of TNS have been observed in all categories of concentration, which confirms the previous finding that altering the lidocaine concentration had no influence on the prevention of TNS \[[@B54-jcm-09-00493]\].

This meta-analysis has a few limitations. First, various definitions of TNS were used in each study. Generally, TNS is defined as pain originating in the gluteal region and radiating to both lower extremities \[[@B2-jcm-09-00493]\]. Some studies included considered TNS as only pain \[[@B4-jcm-09-00493]\], while several other studies regarded TNS as pain and abnormal sensation (hypoesthesia or dysesthesia) \[[@B26-jcm-09-00493],[@B30-jcm-09-00493]\]. Moreover, the anatomical regions (back, thigh, buttock or lower extremity), involving TNS, varied in each study. Furthermore, some studies did not specify details and/or a definition of TNS \[[@B35-jcm-09-00493],[@B47-jcm-09-00493]\]. This variance with respect to TNS may have created bias, influencing the exact frequency of TNS. Second, specific types of surgery and position may be considered as risk factors of TNS, such as knee arthroscopy and lithotomy position. In the present study, various types of surgery and surgical position were included, and this may induce a bias in the results. Subgroup analysis according to the surgical position may provide a better overview. However, surgical position is heterogeneous and is not defined in some trials and the subgroup analysis according to the position, which may induce inaccurate results with bias. Third, only one study compared lidocaine to articaine with 134 patients, which may not be enough to conclude that the frequency of TNS with articaine is less than with lidocaine. Similarly, one RCT compared sameridine with lidocaine with 140 patients and there were no cases of TNS in the sameridine group.

5. Conclusions {#sec5-jcm-09-00493}
==============

In conclusion, the risk of developing TNS after spinal anesthesia with lidocaine was significantly higher than with bupivacaine, levobupivacaine, prilocaine, chloroprocaine, procaine or articaine. In addition, hyperbaric and isobaric lidocaine showed higher TNS rates than other lidocaines.

The following are available online at <https://www.mdpi.com/2077-0383/9/2/493/s1>, Figure S1: Funnel plot of comparison, lidocaine vs. other local anesthetics, Table S1: Search strategy for each database, Table S2: Details for judgement for each risk of bias, Table S3: Sensitivity analysis of comparison.
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![Flow diagram of the included and excluded studies. A total of 4515 articles were found during the literature search. Among them, 2493 articles were duplicated retrievals. A total of 2202 articles and 168 articles were obviously irrelevant studies. We excluded 84 articles due to various reasons. Finally, 39 articles were included in the final analysis. Abbreviations: TNS = transient neurological symptoms, LA = local anesthetics, RCT = randomized controlled trial](jcm-09-00493-g001){#jcm-09-00493-f001}

![Risk of bias summary and graph using the Cochrane Risk of Bias tool \[[@B20-jcm-09-00493]\]. The randomization and allocation concealment were well performed in most studies, but the method was not described in several studies. The performance bias was unclear or high in most studies, whereas the detection bias was low overall. The risk of attrition bias, reporting bias and other biases were low in most studies. Abbreviations: + = low risk of bias, ? = unclear risk of bias, - = high risk of bias.](jcm-09-00493-g002){#jcm-09-00493-f002}

![Forest plot for the risk of transient neurologic symptoms (TNS) after spinal anesthesia with lidocaine versus other local anesthetics. The incidence of TNS 10.8 % in the lidocaine group while 2.2% in the control group. The risk of TNS was significantly higher in the lidocaine group than in the control group (*p* \< 0.001). Abbreviations: LDC = lidocaine, LA = local anesthetics, RR = risk ratio, CI = confidence interval.](jcm-09-00493-g003){#jcm-09-00493-f003}

![Forest plot for subgroup analysis. A subgroup analysis was conducted according to the local anesthetics which were used in the control group. The incidence of TNS was significantly higher in the lidocaine group than in the bupivacaine (*p* \< 0.001), levobupivacaine (*p* \< 0.001), prilocaine (*p* = 0.001), chloroprocaine (*p* = 0.037), procaine (*p* = 0.003) and articaine group (*p* \< 0.001). However, there were no differences in the risk of TNS between the lidocaine group and mepivacaine (*p* =0.728), ropivacaine (*p* = 0.052) and sameridine group (*p* = 0.545). Abbreviations: LDC = lidocaine, LA = local anesthetics, CI = confidence interval.](jcm-09-00493-g004){#jcm-09-00493-f004}

![Forest plot for subgroup analysis. Additional subgroup analyses were conducted according to the baricity or concentration of the lidocaine. The risk of TNS was significantly higher in hyperbaric (*p* \< 0.001), isobaric lidocaine group (*p* \< 0.001) compared to the control group. In terms of concentration, lidocaine showed a higher incidence of TNS regardless of concentrations compared to the control group (*p* \< 0.05). Abbreviations: LDC = lidocaine, LA = local anesthetics, CI = confidence interval.](jcm-09-00493-g005){#jcm-09-00493-f005}

jcm-09-00493-t001_Table 1

###### 

Baseline characteristics of the included randomized trials (*n* = 39).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author        Year   Language     Anesthesia   Type of Operation                                                                                                                                               Number of Groups   Local Anesthetics\     Needle                          Position during Surgery   Follow-up Periods
                                                                                                                                                                                                                                    (Control Group)                                                                  
  ------------- ------ ------------ ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ---------------------- ------------------------------- ------------------------- -----------------------------
  Ali           2015   English      SA ^a^       Knee arthroscopy                                                                                                                                                2                  Bupivacaine            25G Quincke                     Supine                    24,72,168 h

  Aouad         2001   English      SA ^a^       Cesarean section                                                                                                                                                2                  Bupivacaine            25G Whitacre                    Supine                    24,48,72 h

  Beilin        2003   English      CSE ^b^      Cervical cerclage                                                                                                                                               2                  Bupivacaine            25G Sprotte                     Lithotomy                 24 h

  Breebaart     2003   English      SA ^a^       Knee arthroscopy                                                                                                                                                3                  G1: Levobupivacaine\   27G Whitacre                    Supine                    48 h
                                                                                                                                                                                                                                    G2: Ropivacaine                                                                  

  Breebaart     2014   English      SA ^a^       Knee arthroscopy                                                                                                                                                4                  Chloroprocaine         27G Whitacre                    Supine                    168 h

  Buckenmaier   2003   English      SA ^a^       Anorectal surgery                                                                                                                                               2                  Ropivacaine            25G Pencan                      Jackknife                 24,48,72,168 h

  Casati        2007   English      SA ^a^       Knee arthroscopy                                                                                                                                                2                  Chloroprocaine         25G Whitacre                    Not described             24, 168 h

  de Santiago   2009   English      SA ^a^       Tubal sterilization                                                                                                                                             2                  Levobupivacaine        27G Whitacre                    Trendelenburg             168 h

  de Santiago   2010   Spanish      SA ^a^       Anorectal surgery                                                                                                                                               2                  Levobupivacaine        27G Whitacre                    Jackknife                 72, 168 h

  de Weert      2000   English      SA ^a^       Short surgery of the lower body                                                                                                                                 2                  Prilocaine             25G pencil-point                Supine                    24 h

  Etezadi       2013   English      SA ^a^       Varicocele, surgical fixation of lower extremities, transurethral resection of prostate, transurethral lithotripsy, herniorrhaphy                               4                  Bupivacaine            25G Sprotte or Quincke          Supine or lithotomy       8, 16, 24, 32, 40, 48, 72 h

  Fanelli       2009   English      SA ^a^       Knee arthroscopy                                                                                                                                                2                  Ropivacaine            25G Whitacre                    Supine                    24, 168 h

  Gozdemir      2010   English      SA ^a^       Minor orthopedic, varicose vein, inguinal hernia, appendectomy                                                                                                  2                  Levobupivacaine        25G Quincke                     Supine                    48, 168 h

  Gozdemir      2016   English      SA ^a^       Minor orthopedic, cesarean section, varicose vein, inguinal hernia, appendectomy                                                                                4                  G1: Levobupivacaine\   27G pencil-point                Not described             24,48,72 h
                                                                                                                                                                                                                                    G2: Bupivacaine\                                                                 
                                                                                                                                                                                                                                    G3: Articaine                                                                    

  Hampl         1995   English      SA ^a^       Short gynecological procedure                                                                                                                                   3                  Bupivacaine            25G pencil-point                Lithotomy                 24 h

  Hampl         1998   English      SA ^a^       Short gynecological procedure                                                                                                                                   3                  G1: Prilocaine\        25G pencil-point                Lithotomy                 24 h
                                                                                                                                                                                                                                    G2: Bupivacaine                                                                  

  Hodgson       2000   English      SA ^a^       Knee arthroscopy                                                                                                                                                2                  Procaine               24 or 25G pencil-point          Supine                    72 h

  Imbelloni     2010   English      SA ^a^       Anorectal surgery                                                                                                                                               2                  Bupivacaine            27G Quincke                     Jackknife                 Until 30^th^ day

  Keld          2000   English      SA ^a^       Inguinal hernia, femoral hernia, knee arthroscopy, removal of osteosynthetic material, fractures in the lower extremities, incision of infraumbilical abscess   2                  Bupivacaine            25G pencil-point                Supine                    24, 72 h

  Khant         2017   English      SA ^a^       Urologic surgery                                                                                                                                                2                  Bupivacaine            26G Quincke                     Supine or lithotomy       Not described

  Kyokong       2001   English      SA ^a^       Cesarean section                                                                                                                                                2                  Bupivacaine            27G Quincke                     Supine                    24 h

  Le Truong     2001   English      SA ^a^       General, gynecological, or other surgery                                                                                                                        2                  Procaine               27G Whitacre                    Supine or lithotomy       48 h

  Liguori       1998   English      SA ^a^       Knee arthroscopy                                                                                                                                                2                  Mepivacaine            27G Whitacre                    Supine                    48 h

  Maliachi      1999   Portuguese   SA ^a^       Femur surgery                                                                                                                                                   2                  Bupivacaine            22G, not described              Supine                    24, 48, 72 h

  Martin        2005   English      SA ^a^       Knee arthroscopy                                                                                                                                                2                  Prilocaine             25G Whitacre                    Not described             48h

  Martinez      1998   English      SA ^a^       Orthopedic, urologic, gynecologic, vascular, general surgery                                                                                                    2                  Prilocaine             25G pencil-point                Not described             72--120 h

  Mulroy        1999   English      SA ^a^       Inguinal hernia                                                                                                                                                 4                  Sameridine             25G Whitacre                    Supine                    24 h

  Orozco        2006   Spanish      SA ^a^       Surgery below the umbilicus                                                                                                                                     2                  Bupivacaine            Not described                   Not described             Not described

  Ostgaard      2000   English      SA ^a^       Urology surgery                                                                                                                                                 2                  Prilocaine             25,26,27,29G Quincke            Supine or lithotomy       24 h

  Pawlowski     2012   English      CSE ^b^      Anterior cruciate ligament repair                                                                                                                               2                  Mepivacaine            27G Pencan                      Supine                    24,48,72 h

  Philip        2001   English      SA ^a^       Postpartum tubal ligation                                                                                                                                       2                  Bupivacaine            25G Whitacre                    Supine                    24,48 h

  Pollock       1996   English      SA ^a^       Knee arthroscopy or inguinal hernia                                                                                                                             3                  Bupivacaine            22 or 25G Quincke or Whitacre   Supine                    72 h

  Pradhan       2010   English      SA ^a^       Cesarean section                                                                                                                                                2                  Bupivacaine            26G Quincke                     Supine                    Not described

  Punj          2013   English      SA ^a^       pelvic surgery                                                                                                                                                  4                  Bupivacaine            24G Quincke                     Supine                    120 h

  Salazar       2001   English      SA ^a^       Minor surgery of lower extremities                                                                                                                              2                  Mepivacaine            26 or 27G Quincke               Supine                    24 h

  Salmela       1998   English      SA ^a^       Urologic surgery, varicose vein, hemorrhoidectomy, hernia                                                                                                       3                  G1: Mepivacaine\       27G Quincke or Whitacre         Supine or lithotomy       24 h
                                                                                                                                                                                                                                    G2: Bupivacaine                                                                  

  Teunkens      2016   English      SA ^a^       Knee arthroscopy                                                                                                                                                3                  G1: Chloroprocaine\    27G Whitacre                    Supine                    24 h
                                                                                                                                                                                                                                    G2: Bupivacaine                                                                  

  Vaghadia      2012   English      SA ^a^       Transurethral resection of prostate                                                                                                                             2                  Chloroprocaine         25 or 27G Whitacre              Lithotomy                 96--168 h

  Yea           1998   Korean       SA ^a^       Surgery of lower body                                                                                                                                           2                  Mepivacaine            25G Quincke                     Supine                    24 h
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ^a^ SA = spinal anesthesia; ^b^ CSE = combined spinal-epidural anesthesia.
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###### 

Concentration, baricity, doses and adjuvants of study drugs (*n* = 39).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study              Sample Size   LDC ^a^    Control                                                                                                                                        
  ------------------ ------------- ---------- ------------------ ---------------- --------------- ----------------- ---------------------- --------------- ----------------- --------------- -----------------
  Ali 2015           25            25         0.6%               Hypobaric        20 mg           FTN ^b^ 25 µg     Bupivacaine            0.375%          Hyperbaric        3 mg            FTN ^b^ 10 µg

  Aouad 2001         100           100        5%                 Hyperbaric       75 mg           \-                Bupivacaine            0.75%           Hyperbaric        12 mg           \-

  Beilin 2003        29            30         1%                 Isobaric         30 mg           FTN ^b^ 20 µg     Bupivacaine            0.175%          Hyperbaric        5.25 mg         FTN ^b^ 20 µg

  Breebaart 2003     30            G1: 30\    2%                 Isobaric         60 mg           \-                G1: Levobupivacaine\   G1: 0.33%\      G1:Isobaric\      G1: 10 mg\      \-
                                   G2: 30                                                                           G2: Ropivacaine        G2: 0.5%        G2:Isobaric       G2: 15 mg       

  Breebaart 2014     50            50         1.5%               Isobaric         60 mg           \-                Chloroprocaine         1%              Isobaric          40 mg           \-

  Buckenmaier 2003   37            35         2.5%               Hyperbaric       25 mg           FTN ^b^ 20 µg     Ropivacaine            0.5%            Hyperbaric        4 mg            FTN ^b^ 20 µg

  Casati 2007        15            15         1%                 Isobaric         50 mg           \-                Chloroprocaine         1%              Isobaric          50 mg           

  de Santiago 2009   26            26         0.3%               Hypobaric        10 mg           FTN ^b^ 10 µg     Levobupivacaine        0.1%            Hypobaric         3 mg            FTN ^b^ 10 µg

  de Santiago 2010   30            30         0.6%               Hypobaric        18 mg           FTN ^b^ 10 µg     Levobupivacaine        0.5%            Hypobaric         3 mg            FTN ^b^ 10 µg

  de Weert 2000      35            34         2%                 Isobaric         80 mg           \-                Prilocaine             2%              Isobaric          80 mg           \-

  Etezadi 2013       125           125        5%                 Hyperbaric       75--100 mg      \-                Bupivacaine            0.5%            Isobaric          12.5--15 mg     \-

  Fanelli 2009       15            15         1%                 Isobaric         50 mg           \-                Ropivacaine            0.5%            Isobaric          10 mg           \-

  Gozdemir 2010      30            30         2%                 Isobaric         80 mg           \-                Levobupivacaine        0.5%            Isobaric          20 mg           \-

  Gozdemir 2016      100           G1: 100\   2%                 Isobaric         60 mg           \-                G1: Levobupivacaine\   G1: 0.5%\       G1: Isobaric\     G1: 15 mg\      \-
                                   G2: 100\                                                                         G2: Bupivacaine\       G2: 0.5%\       G2: Isobaric\     G2: 15 mg\      
                                   G3: 100                                                                          G3: Articaine          G3: 2%          G3: Isobaric      G3: 60 mg       

  Hampl 1995         G1: 15\       16\        G1:5%\             G1:Hyperbaric\   G1:75 mg\       \-                Bupivacaine            0.5%            Hyperbaric        7.5 mg          \-
                     G2: 13                   (7.5% dextrose)\   G2: Hyperbaric   G2: 75 mg                                                                                                  
                                              G2:5%\                                                                                                                                         
                                              (2.7% dextrose)                                                                                                                                

  Hampl 1998         30            G1: 30\    2%                 Hyperbaric       50 mg           \-                G1: Prilocaine\        G1: 2%\         G1: Hyperbaric\   G1: 50 mg\      \-
                                   G2: 30                                                                           G2: Bupivacaine        G2: 0.5%        G2: Hyperbaric    G2:12.5 mg      

  Hodgson 2000       35            35         2.5%               Hyperbaric       50 mg           \-                Procaine               5%              Hyperbaric        100 mg          

  Imbelloni 2010     75            75         0.6%               Hypobaric        18 mg           \-                Bupivacaine            0.15%           Hypobaric         4.5 mg          \-

  Keld 2000          35            34         5%                 Hyperbaric       100 mg          \-                Bupivacaine            0.5%            Hyperbaric        12.5 mg         \-

  Khant 2017         498           492        3.125%             Not described    25 mg           Butorphanol\      Bupivacaine            0.5%            Not described     5 mg            \-
                                                                                                  0.3 mg                                                                                     

  Kyokong 2001       71            71         5%                 Hyperbaric       60 mg           MP^c^ 0.2 mg\     Bupivacaine            0.5%            Hyperbaric        11 mg           MP^c^ 0.2 mg
                                                                                                  EPI^d^ 0.1 mg                                                                              

  Le Truong 2001     29            25         5%                 Hyperbaric       100 mg          \-                Procaine               5%              Isobaric          100 mg          \-

  Liguori 1998       27            30         2%                 Not described    60 mg           \-                Mepivacaine            1.5%            Not described     45 mg           \-

  Maliachi 1999      20            20         5%                 Not described    1 mg/kg         \-                Bupivacaine            0.5%            Not described     7--15 mg        \-

  Martin 2005        40            40         1.5%               Not described    45 mg           \-                Prilocaine             1.5%            Not described     45 mg           \-

  Martinez 1998      98            100        5%                 Hyperbaric       67.7 ± 8.7 mg   \-                Prilocaine             5%              Hyperbaric        68.6±9.7 mg     \-

  Mulroy 1999        32            G1: 23\    2.5%               Hyperbaric       100 mg          \-                Sameridine             Not described   Isobaric          G1: 15 mg\      \-
                                   G2: 43\                                                                                                                                   G2: 20 mg\      
                                   G3: 42                                                                                                                                    G3: 23 mg       

  Orozco 2006        109           97         5%                 Not described    Not described   \-                Bupivacaine            0.5%            Not described     Not described   \-

  Ostgaard 2000      49            50         2%                 Isobaric         80 mg           \-                Prilocaine             2%              Isobaric          80 mg           \-

  Pawlowski 2012     41            38         2%                 Isobaric         80 mg           \-                Mepivacaine            2%              Isobaric          80 mg           \-

  Philip 2001        29            28         5%                 Hyperbaric       60--80 mg       \-                Bupivacaine            0.75%           Hyperbaric        10.5--12 mg     \-

  Pollock 1996       G1:51\        50\        G1: 5%\            Hyperbaric\      60 or 75 mg     EPI ^d^ or none   Bupivacaine            0.75%           Hyperbaric        7.5 or 9 mg     \-
                     G2:51                    G2: 2%             or isobaric                                                                                                                 

  Pradhan 2010       26            26         5%                 Hyperbaric       75 mg           \-                Bupivacaine            0.5%            Hyperbaric        12.5 mg         \-

  Punj 2013          G1:20\        G1: 20\    G1: 5%\            Hyperbaric       Not described   \-                Bupivacaine            G1: 0.5%\       Hyperbaric        G1: 10 mg\      \-
                     G2:20         G2: 20     G2: 2.5%                                                                                     G2: 0.25%                         G2: 5 mg        

  Salazar 2001       40            40         2%                 Isobaric         40--60 mg       \-                Mepivacaine            2%              Isobaric          40--60 mg       \-

  Salmela 1998       30            G1:30\     2.5%               Hyperbaric       60--100 mg      \-                G1: Mepivacaine\       G1: 4%\         G1: Hyperbaric\   G1:40--80 mg\   \-
                                   G2: 30                                                                           G2: Bupivacaine        G2: 0.5%        G2: Hyperbaric    G2:7.5--17 mg   

  Teunkens 2016      28            G1: 30\    1%                 Isobaric         40 mg           \-                G1: Chloroprocaine\    G1: 1%\         G1: Isobaric\     G1: 40 mg\      
                                   G2: 34                                                                           G2: Bupivacaine        G2: 0.5%        G2: Isobaric      G2: 7.5 mg      

  Vaghadia 2012      20            20         1.75%              Not described    35 mg           FTN ^b^ 12.5 µg   Chloroprocaine         1.77%           Isobaric          40 mg           FTN ^b^ 12.5 µg

  Yea 1998           30            30         1.5%               Hyperbaric       75 mg           \-                Mepivacaine            2%              Hyperbaric                        \-
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ^a^ LDC = Lidocaine; ^b^ FTN = Fentanyl; ^c^ MP = Morphine; ^d^ EPI = Epinephrine.

[^1]: These two authors equally contributed to this work as co-first authors.
